Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy

D Ferrari; V Spagnuolo; M Manca; A Bigoloni; C Muccini; G Banfi; M Locatelli; A Castagna

doi:10.3851/IMP3275

Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy

D Ferrari, V Spagnuolo, M Manca, A Bigoloni, C Muccini, G Banfi, M Locatelli, A Castagna

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA

Original language	English
Pages (from-to)	69-72
Number of pages	4
Journal	Antiviral Therapy
Volume	24
Issue number	1
DOIs	https://doi.org/10.3851/IMP3275
Publication status	Published - 2019

Access to Document

10.3851/IMP3275

http://www.scopus.com/inward/record.url?scp=85061760076&partnerID=8YFLogxK

Cite this

@article{7f1b7833d81a4bdfb621b68f86295f88,

title = "Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy",

abstract = "BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA ",

author = "D Ferrari and V Spagnuolo and M Manca and A Bigoloni and C Muccini and G Banfi and M Locatelli and A Castagna",

year = "2019",

doi = "10.3851/IMP3275",

language = "English",

volume = "24",

pages = "69--72",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "International Medical Press Ltd",

number = "1",

}

TY - JOUR

T1 - Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients

T2 - Antiviral therapy

AU - Ferrari, D

AU - Spagnuolo, V

AU - Manca, M

AU - Bigoloni, A

AU - Muccini, C

AU - Banfi, G

AU - Locatelli, M

AU - Castagna, A

PY - 2019

Y1 - 2019

N2 - BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA

AB - BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA

U2 - 10.3851/IMP3275

DO - 10.3851/IMP3275

M3 - Article

VL - 24

SP - 69

EP - 72

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -

Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy

Abstract

Access to Document

Fingerprint

Cite this